Abstract 12214: ODYSSEY EAST - A Randomized, Double-blind, Parallel Group Study to Evaluate Alirocumab Efficacy and Safety Versus Ezetimibe In High-Risk Patients With Hypercholesterolemia on Maximally Tolerated Statin in China, India, and Thailand

Yaling Han,Jiyan Chen,VijayKumar Chopra,Shuyang Zhang,Guohai Su,Chang Sheng Ma,Zhouqing Huang,Yingyan Ma,Zhuhua Yao,Zuyi Yuan,Qiang Zhao,Srun Kuanprasert,Marie T. Baccara-Dinet,Garen Manvelian,Jianyong Li,Rui Chen

Abstract 12214: ODYSSEY EAST - A Randomized, Double-blind, Parallel Group Study to Evaluate Alirocumab Efficacy and Safety Versus Ezetimibe In High-Risk Patients With Hypercholesterolemia on Maximally Tolerated Statin in China, India, and Thailand

2019

Yaling Han
Jiyan Chen
VijayKumar Chopra
Shuyang Zhang
Guohai Su
Chang Sheng Ma
Zhouqing Huang
Yingyan Ma
Zhuhua Yao
Zuyi Yuan
Qiang Zhao
Srun Kuanprasert
Marie T. Baccara-Dinet
Garen Manvelian
Jianyong Li
Rui Chen

Introduction: The PCSK9 inhibitor alirocumab (ALI) has been shown to provide significant low-density lipoprotein cholesterol (LDL-C) reductions. This study was conducted to assess ALI efficacy and ...

Keywords:

Alirocumab
Statin
PCSK9
Medicine
Internal medicine
Diabetes mellitus
Cardiology
group study
Clinical trial
high risk patients
Ezetimibe

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations